199 related articles for article (PubMed ID: 33058053)
1. Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.
Algahtani H; Shirah B; Sukkar G; Bukhari H; Meftah I; Alhazmi A; Alshareef A; Algethami A; Alshanqiti A; Andeejani M
Acta Neurol Belg; 2021 Dec; 121(6):1783-1787. PubMed ID: 33058053
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Silberstein S; Mathew N; Saper J; Jenkins S
Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
[TBL] [Abstract][Full Text] [Related]
3. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
Bernhard MK; Bertsche A; Syrbe S; Weise S; Merkenschlager A
Fortschr Neurol Psychiatr; 2014 Jan; 82(1):39-42. PubMed ID: 24446117
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study.
Lee MJ; Lee C; Choi H; Chung CS
J Neurol Sci; 2016 Apr; 363():51-4. PubMed ID: 27000220
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
Blumenfeld A
Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
Suzuki K; Iizuka T; Sakai F
Intern Med; 2007; 46(13):959-63. PubMed ID: 17603233
[TBL] [Abstract][Full Text] [Related]
7. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
Elkind AH; O'Carroll P; Blumenfeld A; DeGryse R; Dimitrova R;
J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
[TBL] [Abstract][Full Text] [Related]
8. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Mitchell MP; Schaecher K; Cannon HE; Speckman M
J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
[TBL] [Abstract][Full Text] [Related]
9. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
[TBL] [Abstract][Full Text] [Related]
10. Single-site botulinum toxin type a injection for elimination of migraine trigger points.
Behmand RA; Tucker T; Guyuron B
Headache; 2003; 43(10):1085-9. PubMed ID: 14629244
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
Binder WJ; Brin MF; Blitzer A; Schoenrock LD; Pogoda JM
Otolaryngol Head Neck Surg; 2000 Dec; 123(6):669-76. PubMed ID: 11112955
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
13. Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study.
Horvat DE; Shields JM; Young WWC; Eye PG
Pediatr Neurol; 2023 Oct; 147():68-71. PubMed ID: 37562172
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment of migraine headaches.
Guyuron B; Tucker T; Davis J
Plast Reconstr Surg; 2002 Jun; 109(7):2183-9. PubMed ID: 12045534
[TBL] [Abstract][Full Text] [Related]
15. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
Artemenko AR; Abramov VG; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Yakovleva PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(5):89-99. PubMed ID: 37315247
[TBL] [Abstract][Full Text] [Related]
16. The Use of Botulinum Toxin Type A in Medically Refractory Pediatric Patients With Chronic Daily Headaches and Its Impact on the Quality of Life.
Akbar A; Ford J; Tripathi S
J Child Neurol; 2024 Jan; 39(1-2):55-60. PubMed ID: 38351705
[No Abstract] [Full Text] [Related]
17. Predicting migraine responsiveness to botulinum toxin type A injections.
Kim CC; Bogart MM; Wee SA; Burstein R; Arndt KA; Dover JS
Arch Dermatol; 2010 Feb; 146(2):159-63. PubMed ID: 20157026
[TBL] [Abstract][Full Text] [Related]
18. Acupoint injection of onabotulinumtoxin A for migraines.
Hou M; Xie JF; Kong XP; Zhang Y; Shao YF; Wang C; Ren WT; Cui GF; Xin L; Hou YP
Toxins (Basel); 2015 Oct; 7(11):4442-54. PubMed ID: 26529014
[TBL] [Abstract][Full Text] [Related]
19. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites.
Liu MT; Armijo BS; Guyuron B
Plast Reconstr Surg; 2012 Feb; 129(2):413-419. PubMed ID: 21987048
[TBL] [Abstract][Full Text] [Related]
20. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.
Pijpers JA; Kies DA; Louter MA; van Zwet EW; Ferrari MD; Terwindt GM
Brain; 2019 May; 142(5):1203-1214. PubMed ID: 30982843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
